Physician profile
Fallan Mayabb
NPI 1437440245
$3,394.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.98 · 2020: $37.56 · 2021: $3,086 · 2022: $101 · 2023: $82.99 · 2024: $68.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,056.50 | 2021 | |
| Organon LLC | $75.81 | 2022-2024 | Nexplanon |
| Roche Diagnostics Corporation | $56.54 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.07 | 2022 | |
| Exeltis, USA INC. | $30.51 | 2022-2023 | Slynd |
| Baudax Bio INC. | $29.23 | 2021 | |
| Agile Therapeutics, INC. | $18.01 | 2022 | |
| Pfizer INC. | $16.90 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.57 | 2023 | |
| Astellas Pharma US INC | $14.73 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.48 | 2024 | Xifaxan |
| Scynexis, INC. | $13.66 | 2022 | |
| Abbvie INC. | $13.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fallan Mayabb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.